AO imaging in AMD: towards personalized medicine

Webinar replay available

In this 30-min roundtable discussion, Profs. Andrew Lotery, Paulo E. Stanga and Michel Paques, 3 ophthalmology experts, shared their experience and vision about adaptive optics (AO) imaging for age-related macular degeneration (AMD).

The webinar adressed the use of rtx1 AO cameras for the observation of phenotypes and the evaluation of progression at the microscopic scale in AMD. The panelists discussed how such detailed retinal information could enable the development of highly personalized therapeutic approaches, and accelerate clinical evaluations.

AO imaging using the rtx1 has provided invaluable insights into the mechanisms of GA and will likely become a reference tool for trials, in particular at early stages of AMD.

Successfully imaging photoreceptor and RPE cells has become essential in an era of gene therapy and complement modulation.

 

About our guests:

Andrew Lotery, MD, FRCOphth, is Professor of Ophthalmology at NHS University Hospital Southampton research interests include investigating the molecular basis of AMD, a condition he develops treatments for by conducting clinical trials. He currently leads an international research project funded by the Wellcome Trust, PINNACLE, that evaluates adaptive optics imaging as a tool to better understand the progression of AMD.

Michel Paques, MD, PhD, is Professor of Ophthalmology and researcher at Quinze-Vingts National Eye Hospital and Vision Institute, in France. His focus is on medical applications of high resolution in vivo retinal imaging in humans. He pioneered the development of cell-specific imaging using SLO, and the application of adaptive optics ophthalmoscopy for a variety of retinal diseases, including geographic atrophy secondary to AMD.

Paulo Eduardo Stanga, MD, PhD, is Director of The Retina Clinic London and Professor of Ophthalmology at the University College London. Since 1993, in addition to treating patients, he has worked in the development and application of new clinical and surgical therapies and technologies, such as AO imaging of photoreceptors and retinal pigment epithelium. His current research activities include, amongst others, clinical studies on gene therapy surgery & anti-complement injections for dry AMD.